Medical device innovation is key to advancing healthcare and fostering economic development. As the global medical technology market expands, the capacity of regions and countries to attract and support innovation has become increasingly significant. This article examines the growing perception that China is becoming a more attractive environment for medical device development than Europe, focusing on key regulatory differences that may influence this shift. It compares the hierarchical structure of legislation, regulatory oversight bodies, and classification procedures, particularly for emerging technologies like artificial intelligence (AI). For instance, while Europe’s decentralised system of notified bodies offers developers flexibility, China’s centralised regulatory agencies and more adaptable classification system – alongside the absence of stringent AI-specific regulations like the EU’s AI Act – may present a different set of trade-offs and facilitate faster market entry for innovative technologies. Despite these differences, the paper argues that regulation alone does not fully explain China’s rising attractiveness. Other contributing factors, such as its vast market size, significant government support, and broader R&D policies, must also be considered. The analysis concludes that while regulatory structures are influential, they represent just one component of a multifaceted ecosystem that shapes the global geography of medical device innovation.